glp 1 chemical structure The GLP-1 weight loss revolution | Feature GLP-1 antagonist | GLP-1 antagonist

Clinical studies have proven that there has been a significant decrease in body weight for participants using semaglutide GLP-1 compared to those on a placebo

doi:10.1007/s40265-020-01260-9

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) begin affecting appetite and blood sugar within days to weeks, but clinically meaningful outcomes develop more gradually

So far, the most common side effects seen in clinical trials have been digestive symptoms, such as nausea, vomiting, diarrhoea, constipation, bloating, burping and indigestion

Trust and Transparency The clinics commitment to patient education and empowerment is evident through its comprehensive resources, including virtual workshops, nutrition guides, and one-on-one coaching sessions

It is meant to be used alongside a reduced-calorie diet and increased physical activity, not as a standalone fix